<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00475371</url>
  </required_header>
  <id_info>
    <org_study_id>MKC-253-001</org_study_id>
    <secondary_id>EudraCT Number 2007-000361-37</secondary_id>
    <nct_id>NCT00475371</nct_id>
  </id_info>
  <brief_title>A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males</brief_title>
  <official_title>A Phase 1a, Single-Dose, Open-Label, Parallel, Ascending Dose, Controlled Safety and Tolerability Trial of Inhaled MKC253 in Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mannkind Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mannkind Corporation</source>
  <brief_summary>
    <textblock>
      26 subjects will be enrolled into 5 different dose groups. The trial will consist of a&#xD;
      screening, a dosing and a follow-up visit.&#xD;
&#xD;
      Dosing at visit 2, of MKC253 Inhalation Powder, Glucagon-Like Peptide-1 (GLP-1) will be given&#xD;
      at 5 dose levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 1a , single-dose trial incorporates an open-label, ascending dose strategy to&#xD;
      determine the safety &amp; tolerability of MKC253 (GLP1/TechnosphereÂ®)Inhalation Powder.&#xD;
&#xD;
      The trial consists of a screening, dosing and a follow-up visit. Single dose administration&#xD;
      of MKC253 occurs at the dosing visit. Five doses are being assessed: 0.05, 0.45, 0.75, 1.05 &amp;&#xD;
      1.5 mg GLP-1. Dosing of each ascending cohort will occur after the Principal Investigator has&#xD;
      reviewed all safety/tolerability data&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the safety and tolerability of ascending doses of MKC253 Inhalation Powder</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of pulmonary and other AEs</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameters of plasma GLP-1</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Healthy Males</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MKC253 Inhalation Powder</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MKC253 Inhalation Powder</intervention_name>
    <description>Inhalation powder</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males = 18 and = 45 years of age&#xD;
&#xD;
          -  Written Informed Consent.&#xD;
&#xD;
          -  Body Mass Index (BMI) of &lt; 30 kg/m2&#xD;
&#xD;
          -  Non-smoker&#xD;
&#xD;
          -  Normal pulmonary function and performance on pulmonary function tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant disease including diabetes mellitus&#xD;
&#xD;
          -  Fasting blood glucose &gt; 110 mg/dL (6.1 mmol/L)&#xD;
&#xD;
          -  Significant psychiatric condition or drug or alcohol abuse&#xD;
&#xD;
          -  Any other condition which, in the opinion of the PI, makes the subject unsuitable for&#xD;
             the clinical trial, or could limit the validity of the informed consent and/or impair&#xD;
             the subject's ability to participate in the trial&#xD;
&#xD;
          -  Inability to perform PFT maneuvers meeting recommended American Thoracic Society (ATS)&#xD;
             standards of acceptability and repeatability criteria&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Baughman</last_name>
    <role>Study Director</role>
    <affiliation>Mannkind Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Centre Groningen</name>
      <address>
        <city>Zuidlaren</city>
        <zip>9470 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>May 16, 2007</study_first_submitted>
  <study_first_submitted_qc>May 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2007</study_first_posted>
  <last_update_submitted>June 12, 2012</last_update_submitted>
  <last_update_submitted_qc>June 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Diabetes Mellitus: Type II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

